Equities research analysts at StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV - Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
MediciNova Stock Up 0.6 %
Shares of MediciNova stock traded up $0.01 on Wednesday, reaching $1.76. 8,559 shares of the stock were exchanged, compared to its average volume of 38,807. The business has a 50 day moving average price of $1.76 and a two-hundred day moving average price of $1.49. The firm has a market capitalization of $86.32 million, a price-to-earnings ratio of -10.29 and a beta of 0.75. MediciNova has a twelve month low of $1.12 and a twelve month high of $2.16.
MediciNova (NASDAQ:MNOV - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Research analysts forecast that MediciNova will post -0.23 EPS for the current year.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Stories
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
